Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios
申请人:STEMINA BIOMARKER DISCOVERY, INC.
公开号:US10209240B2
公开(公告)日:2019-02-19
This present invention provides rapid, reproducible, biomarker-based screening methods for the developmental toxicity testing of compounds. The methods are designed to identify the exposure level at which a test compound perturbs metabolism in a manner predictive of developmental toxicity. In particular, the perturbation of two metabolites, ornithine and cystine, is measured, wherein a ratio of the fold change in ornithine to the fold change in cystine of less than or equal to about 0.88 is indicative of the teratogenicity of a test compound.
本发明为化合物的发育毒性测试提供了快速、可重复、基于生物标记的筛选方法。这些方法旨在确定试验化合物以可预测发育毒性的方式扰乱新陈代谢的暴露水平。特别是,测量鸟氨酸和胱氨酸这两种代谢物的扰动,其中鸟氨酸的折叠变化与胱氨酸的折叠变化之比小于或等于约 0.88,则表明试验化合物具有致畸性。